Investors Balk At AMAG-Allos Proposed Marriage
This article was originally published in The Pink Sheet Daily
Executive Summary
An all-stock merger worth up to $686 million would strengthen the companies' balance sheet, commercial presence, and cost structures, but Wall Street is concerned about logistics and execution.
You may also be interested in...
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
AMAG shareholders have killed plans for what they considered an ill-conceived merger and one shareholder calls the vote a "clear signal" that current management isn't fit to run the company.
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
AMAG shareholders have killed plans for what they considered an ill-conceived merger and one shareholder calls the vote a "clear signal" that current management isn't fit to run the company.
Sell The Launch: Going Commercial, Some Biotechs Are Left Hanging
A wave of biotechs is making the milestone move from drug developer to drug marketer, but investors are less interested than ever in sticking around for the potential long-term rewards.